Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Sanofi's MenQuadfi receives EU approval for infants from six weeks against invasive meningococcal disease
Vaccine, infectious disease, meningococcal disease, pediatric population, bacterial infection - Read more

Qnovia licenses novel antimicrobial peptide D8 from University of Virginia for global exclusive development
Licensing deal, infectious disease, antimicrobial peptide, preclinical, commercialization - Read more

Pathos AI, AstraZeneca, Jiangsu Alphamab Biopharmaceuticals ink dual breast cancer deals, $125M upfront, $2.093B milestones
Licensing deal, oncology, AI/ML, antibody-drug conjugate, milestone payments, royalties - Read more

Sethera Therapeutics, Receptor.AI partner to accelerate polymacrocyclic peptide discovery using AI-driven closed-loop platform
Research collaboration, AI/ML, drug discovery, peptide, hard-to-drug targets - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Otsuka's Voyxact (sibeprenlimab) stabilizes kidney function decline to normal levels in Ph3 immunoglobulin A nephropathy trial
Antibody, autoimmune, monoclonal antibody, IgA nephropathy, APRIL target - Read more

Rocket Pharmaceuticals reports positive Ph2 safety data for RP-A501 (RP-A501) in Danon disease cardiomyopathy
Gene therapy, cardiovascular, adeno-associated virus, Danon disease, cardiomyopathy, immunomodulation - Read more

Merck & Co. raises 2026 sales guidance to $67.3B as Keytruda, Winrevair, and Lipfendra drive growth
Monoclonal antibody, oncology, cardiovascular, financial, major transaction - Read more

Latigo Biotherapeutics plans $247M IPO to fund non-opioid pain pipeline rivaling Vertex's Journavx
Non-opioid pain, small molecule, Nav1.8 inhibitor, clinical-stage - Read more

Dash Bio raises $30M Series A to scale automated bioanalysis platform for drug development
CRO, bioanalysis, automation, preclinical, platform technology - Read more

Apnimed raises $220.8M IPO, developing oral therapies for sleep-related breathing diseases
Sleep disorders, small molecule, neurological, clinical-stage - Read more

Inocras closes $31M Series B-3 financing to expand whole-genome sequencing bioinformatics platform
Bioinformatics, whole-genome sequencing, precision health, data analytics, diagnostics - Read more

KKR acquires medtech manufacturer Integer private in $5.7B deal
Medtech manufacturing, cardiovascular, major transaction, private equity - Read more

Bayer CEO defends turnaround strategy amid flat pharma Q2 sales, eyes second-half growth acceleration
Pharma conglomerate, oncology, cardiovascular, financial, cost reduction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Merck & Co,'s tulisokibart (tulisokibart) scores Ph2b win in hidradenitis suppurativa, fails in systemic sclerosis-associated interstitial lung disease
Antibody, autoimmune, monoclonal antibody, ulcerative colitis, hidradenitis suppurativa, TL1A - Read more

Jazz Pharmaceuticals withdraws Zepzelca (lurbinectedin) label indication for second-line small cell lung cancer after Ph3 failure
Small molecule, cancer, chemotherapy, small cell lung cancer, label withdrawal, monotherapy - Read more

BioNTech cuts 2025 sales forecast by €400M ($461M) amid slumping COVID-19 vaccine demand globally
mRNA vaccine, infectious disease, revenue impact, competitive - Read more

Lisata lays off 72% of staff, sues Kuva Labs after planned merger collapses
Peptide therapy, oncology, cost reduction, major transaction - Read more

Pfizer discontinues Ph2 GIPR antagonist (PF-07976016) and ex-Metsera GLP-1 asset (MET-224o) for obesity
Small molecule, metabolic, GLP-1 receptor agonist, GIPR antagonist, obesity - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here